Amged Abdelaziz, MD
Interventional Cardiology · Portland, ORNPI 1972703536
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (57.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 62.7% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $28,924 and has fallen 96.2% since, to $1,105 in 2025.
Across 177 payments — averaging $215.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$24K
- Boston Scientific$5K
- Edwards Lifesciences$3K
- Abbott$2K
- W. L. Gore & Associates, Inc.$1K
- Abiomed$575
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$1,1323%
- Grants$22,00058%
- Travel & lodging$8,66623%
- Food & beverage$6,35517%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $23,917 |
| Boston Scientific | 21 | $4,501 |
| Edwards Lifesciences | 28 | $3,448 |
| Abbott | 10 | $1,514 |
| W. L. Gore & Associates, Inc. | 7 | $1,324 |
| Abiomed | 13 | $575 |
| AstraZeneca | 10 | $455 |
| Alnylam Pharmaceuticals Inc. | 12 | $390 |
| Novo Nordisk | 9 | $281 |
| E.r. Squibb & Sons, L.L.C. | 6 | $230 |
| Johnson & Johnson | 6 | $191 |
| Boehringer Ingelheim | 4 | $170 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $137 |
| Kestra Medical Technology Services, Inc. | 6 | $120 |
| Cook Medical LLC | 3 | $115 |
| Bridgebio Pharma, Inc. | 2 | $113 |
| Cardiva Medical, Inc. | 1 | $99 |
| Merck | 2 | $91 |
| Lilly USA, LLC | 1 | $90 |
| Biotronik Inc. | 1 | $81 |
| Actelion Pharmaceuticals US, Inc. | 1 | $68 |
| Pfizer | 2 | $40 |
| Penumbra, Inc. | 2 | $32 |
| Amgen | 2 | $31 |
| Bayer | 1 | $25 |
| Angiodynamics, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Teleflex LLC | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANGIOJET$2,639
- VersaCross Access Solution$1,547
- COREVALVE EVOLUT R$1,401
- MitraClip$1,248
- GORE CARDIOFORM Septal Occluder$1,200
- PASCAL$1,132
- Edwards SAPIEN 3 Transcatheter Heart Valve$695
- SAPIEN 3 Ultra RESILIA$288
- Impella$234
- Varithena Administration Pack$148
- LifeVest$126
- AMVUTTRA$125
- WAINUA$125
- CAMZYOS$125
- FARXIGA$124
- XARELTO$111
- LOKELMA$107
- JARDIANCE$101
How this compares
$38,164 in reported general payments places this provider in the 80th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $82,086 |
| XareltoRivaroxaban | 46 | $47,009 |
| EntrestoSacubitril/Valsartan | 50 | $40,919 |
| FarxigaDapagliflozin Propanediol | 50 | $39,169 |
| JardianceEmpagliflozin | 22 | $15,952 |
| BrilintaTicagrelor | 24 | $13,321 |
| Atorvastatin Calcium | 140 | $1,836 |
| Metoprolol Succinate | 137 | $1,556 |
| ClopidogrelClopidogrel Bisulfate | 115 | $1,350 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 23 | $907 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 49 | $647 |
| Losartan Potassium | 59 | $602 |
| Carvedilol | 75 | $534 |
| Nitroglycerin | 24 | $521 |
| Rosuvastatin Calcium | 31 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $40 | $82,086105 claims |
| AstraZenecaFarxiga, Brilinta | $455 | $52,49074 claims |
| Johnson & JohnsonXarelto | $191 | $47,00946 claims |
| Boehringer IngelheimJardiance | $170 | $15,95222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Portland
- Jason WollmuthPortland$749K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
- Harsh GolwalaPortland$105K
- Brandon JonesPortland$101K
- Kathryn DawsonPortland$57K
- Logan VincentPortland$42K
- Richard SohnPortland$38K
- Daniel FeldmanPortland$36K
- Kris KumarPortland$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.